Nuvo Pharmaceuticals Competitors, Revenue, Alternatives and Pricing

Claim your profile


Toronto, ON CAN
Total Funding:N/A
Lead Investor(s):N/A

Estimated Revenue & Financials

  • Nuvo Pharmaceuticals's estimated annual revenue is currently $14.1M per year.(?)
  • Nuvo Pharmaceuticals received $6.0M in venture funding in August 2017.
  • Nuvo Pharmaceuticals's estimated revenue per employee is $201,000

Employee Data

  • Nuvo Pharmaceuticals has 70 Employees.(?)
  • Nuvo Pharmaceuticals grew their employee count by 19% last year.
  • Nuvo Pharmaceuticals currently has 1 job openings.

Nuvo (TSX:NRI) is a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities. Nuvo has three commercial products that are available in a number of countries; Pennsaid 2%, Pennsaid and the heated lidocaine/tetracaine patch. Pennsaid 2% is sold in the U.S. by Horizon Pharma plc (NASDAQ:HZNP) and is available for partnering in certain other territories around the world. Nuvo manufactures Pennsaid for the global market and Pennsaid 2% for the U.S. market at its FDA licensed GMP facility in Varennes, Québec.